These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 32387332)

  • 61. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Audio Interview: What the U.S. Response to Covid-19 Looks Like Today.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Nov; 383(19):e123. PubMed ID: 33211936
    [No Abstract]   [Full Text] [Related]  

  • 63. COVID-19 vaccines: Knowing the unknown.
    Lv H; Wu NC; Mok CKP
    Eur J Immunol; 2020 Jul; 50(7):939-943. PubMed ID: 32437587
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).
    Ahn DG; Shin HJ; Kim MH; Lee S; Kim HS; Myoung J; Kim BT; Kim SJ
    J Microbiol Biotechnol; 2020 Mar; 30(3):313-324. PubMed ID: 32238757
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An Urgent Need for "Common Cold Units" to Study COVID-19.
    Halstead SB
    Am J Trop Med Hyg; 2020 Jun; 102(6):1152-1153. PubMed ID: 32274988
    [No Abstract]   [Full Text] [Related]  

  • 66. COVID-19 vaccine design: the Janus face of immune enhancement.
    Hotez PJ; Corry DB; Bottazzi ME
    Nat Rev Immunol; 2020 Jun; 20(6):347-348. PubMed ID: 32346094
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Coronavirus Disease 2019 pandemic: how does it spread and how do we stop it?
    Li X; Sridhar S; Chan JF
    Curr Opin HIV AIDS; 2020 Nov; 15(6):328-335. PubMed ID: 32969975
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Equitable Distribution of COVID-19 Therapeutics and Vaccines.
    Bollyky TJ; Gostin LO; Hamburg MA
    JAMA; 2020 Jun; 323(24):2462-2463. PubMed ID: 32379268
    [No Abstract]   [Full Text] [Related]  

  • 69. SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment.
    di Mauro G; Scavone C; Rafaniello C; Rossi F; Capuano A
    Int Immunopharmacol; 2020 Jul; 84():106519. PubMed ID: 32311668
    [TBL] [Abstract][Full Text] [Related]  

  • 70. SARS-CoV-2: a time for clear and immediate action.
    Poland GA
    Lancet Infect Dis; 2020 May; 20(5):531-532. PubMed ID: 32243818
    [No Abstract]   [Full Text] [Related]  

  • 71. Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines.
    Chen X; Han W; Wang G; Zhao X
    Int J Biol Macromol; 2020 Dec; 164():331-343. PubMed ID: 32679328
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.
    Rabaan AA; Al-Ahmed SH; Sah R; Tiwari R; Yatoo MI; Patel SK; Pathak M; Malik YS; Dhama K; Singh KP; Bonilla-Aldana DK; Haque S; Martinez-Pulgarin DF; Rodriguez-Morales AJ; Leblebicioglu H
    Ann Clin Microbiol Antimicrob; 2020 Sep; 19(1):40. PubMed ID: 32878641
    [TBL] [Abstract][Full Text] [Related]  

  • 73. From SARS to COVID-19: What lessons have we learned?
    Liu Q; Xu K; Wang X; Wang W
    J Infect Public Health; 2020 Nov; 13(11):1611-1618. PubMed ID: 32888871
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ending COVID-19: progress and gaps in research-highlights of the July 2020 GloPID-R COVID-19 Research Synergies Meetings.
    ;
    BMC Med; 2020 Oct; 18(1):342. PubMed ID: 33115460
    [No Abstract]   [Full Text] [Related]  

  • 75. Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines.
    Kremer EJ
    Mol Ther; 2020 Nov; 28(11):2303-2304. PubMed ID: 33065038
    [No Abstract]   [Full Text] [Related]  

  • 76. COVID-19: Some clinical questions after the first 4 months.
    Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
    Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
    [No Abstract]   [Full Text] [Related]  

  • 77. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19.
    Neumann-Böhme S; Varghese NE; Sabat I; Barros PP; Brouwer W; van Exel J; Schreyögg J; Stargardt T
    Eur J Health Econ; 2020 Sep; 21(7):977-982. PubMed ID: 32591957
    [No Abstract]   [Full Text] [Related]  

  • 78. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.
    Wang F; Kream RM; Stefano GB
    Med Sci Monit; 2020 May; 26():e924700. PubMed ID: 32366816
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Importance of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19.
    Schlom J; Donahue RN
    J Infect Dis; 2020 Oct; 222(9):1435-1438. PubMed ID: 32651586
    [TBL] [Abstract][Full Text] [Related]  

  • 80. COVID-19: How has the scientific community risen to the challenge?
    Straiton J
    Biotechniques; 2020 May; 68(5):232-234. PubMed ID: 32319301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.